Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation

25 Jan 2017

Abstract excerpt

Abstract In multiple myeloma, osteolytic lesions rarely heal because of persistent suppressed osteoblast differentiation resulting in a high fracture risk. Herein, chromatin immunoprecipitation analyses reveal that multiple myeloma cells induce repressive epigenetic histone changes at the Runx2 locus that prevent osteoblast differentiation. The most pronounced multiple myeloma–induced changes were at the Runx2-P1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28119431
DOI: 10.1158/1541-7786.mcr-16-0242-t

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast DifferentiationPMID 28119431Read ↗

Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone DiseaseSemantic proximity Read ↗

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destructionSemantic proximity Read ↗

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone diseaseSemantic proximity Read ↗

Osteoblast suppression in multiple myeloma bone diseaseSemantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Reprogrammed marrow adipocytes contribute to myeloma-induced bone diseaseSemantic proximity Read ↗

Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease.Semantic proximity Read ↗

Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.